Actelion Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd

Sylvaine Cren

Olivier Corminboeuf

Daniel Bur

Xavier Leroy

Sylvia Richard-Bildstein

Corinna Grisostomi

Davide Pozzi

Georg Rueedi

Cornelia Zumbrunn

Julien Pothier

Astrid Friedli

Christian N Hubschwerlen

Christoph Boss

Heinz Fretz

Thierry Kimmerlin

Carina Lotz-Jenne

Oliver Corminboeuf

Naomi Tidten-Luksch

The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed. 

Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase

The invention relates to antibacterial compounds of formula I wherein R, R, R, R, R, R, R, U, U, U, U, V, V, V, V, X and Q and n are as defined in the specification. It further relates pharmaceutical compositions containing these compounds and the uses of these compounds in the manufacture of medicaments for the treatment of bacterial infections. These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram-positive and Gram-negative aerobic and anaerobic bacteria.

Antibacterial basic biaromatic derivatives with aminoalkoxy substitution

The present invention relates to difluoroethyl-oxazole substituted bridged spiro[2.4] heptane derivatives of formula (I), wherein the substituents at the piperidine ring are in trans-arrangement, their preparation and their use as pharmaceutically active compounds.

Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R, R, R, R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Benzimidazolyl-methyl urea derivatives as ALX receptor agonists

The present invention relates to a piperazine substituted bridged spiro[2.4]heptane derivative of formula (I), its preparation and its use as pharmaceutically active compound.

Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists

The invention relates to antibacterial compounds of formula I and salts thereof and methods of treating bacterial infection using the compounds. 

Antibacterial biaromatic derivatives

The invention relates to hydroxylated aminotriazole derivatives of formula (I), wherein Q, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Hydroxylated aminotriazole derivatives as ALX receptor agonists

The present invention relates to 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives of formula (I), wherein Ris as defined in the description, their preparation and their use as pharmaceutically active compounds.

1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.

Bridged Spiro[2.4]heptane ester derivatives

The invention relates to oxazolyl-methylether derivatives of formula (I), wherein R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Oxazolyl-methylether derivatives as ALX receptor agonists

The invention relates to oxazole and thiazole derivatives of formula (I), wherein A, E, X, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds. 

Oxazole and thiazole derivatives as ALX receptor agonists

The invention relates to fluorinated aminotriazole derivatives of formula (I), wherein A, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds. 

Fluorinated aminotriazole derivatives

The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases. 

Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists

The invention relates to aminotriazole derivatives of formula (I), wherein A, E, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Aminotriazole derivatives as ALX agonists

The invention relates to aminopyrazole derivatives of formula (I), wherein A, E, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Growing community of inventors

Allschwil, Switzerland

Sylvaine Cren